Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Why do so many clinical trials of therapies for Alzheimer’s disease fail?

Alzheimer’s disease is an irreversible, progressive brain disorder that accounts for about 50–75% of all cases of dementia.1 Alzheimer’s disease is characterised by the presence of amyloid plaques (amyloid β) and neurofibrillary (tau) tangles, plus the loss of connections between neurons in the brain. The damage to the brain induced by abnormal deposits of amyloid β and tau tangles is believed to start a decade or more before a decline in cognitive function is apparent.1,2